Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer - Rossi, E; Fassan, M; Aieta, M; Zilio, F; Celadin, R; Borin, M; Grassi, A; Troiani, L; Basso, U; Barile, C; Sava, T; Lanza, C; et al. (British journal of cancer, 2012)
Keywords: 692/53/2423; 692/699/67/1059/99; 692/699/67/589/1588; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors - therapeutic use; Apoptosis; Biological and medical sciences; Biomarkers, Tumor; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cancer therapies; Chemotherapy; Clinical Study; Disease Progression; Drug Resistance; Endothelial Cells - pathology; Epidemiology; Female; Humans; Indoles - therapeutic use; Keratin-18; Kidney cancer; Kidney Neoplasms - drug therapy; Kidney Neoplasms - pathology; Kidney Neoplasms - secondary; Kidneys; Male; Medical prognosis; Medical research; Medical sciences; Metastasis; Middle Aged; Molecular Medicine; Neoplastic Cells, Circulating - pathology; Nephrology. Urinary tract diseases; Observational studies; Oncology; Patients; Pharmacodynamics; Prospective Studies; Pyrroles - therapeutic use; Treatment Failure; Tumors; Tumors of the urinary system; Italy; sunitinib; circulating endothelial cells (CEC); renal cancer; circulating tumour cells (CTC); M30; Antineoplastic agent; Endothelial cell; Tumoral marker; Metastasis; Sunitinib; Cancerology; Dynamics; Advanced stage; Antiangiogenic agent; Protein-tyrosine kinase; Tumor cell; Kidney disease; Urinary system disease; Enzyme; Tyrosine kinase inhibitor; Transferases; Enzyme inhibitor; Malignant tumor; Kidney cancer; Multikinase inhibitor; Cancer; Apoptosis